BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears [Yahoo! Finance]
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $86.00. They now have a "buy" rating on the stock.
Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge [Yahoo! Finance]